Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Zai Lab Approved to Launch Fc Receptor Agonist for Myasthenia Gravis Patients

publication date: Jul 3, 2023

Shanghai Zai Lab was approved to launch Vyvgart® in China as an add-on to standard of care treatment for generalized myasthenia gravis in adult patients who are anti-acetylcholine receptor antibody positive. Vyvgart® (efgartigimod alfa injection) is a first-in-class neonatal Fc receptor (FcRn) antagonist. Two years ago, Zai acquired Vyvgart® from Amsterdam’s argenx SE in a $175 million deal. Zai said it will now work with government officials to include the drug in China’s National Reimbursement Drug List. More details....

Stock Symbols: (NSDQ: ZLAB; HK: 9688) (Euronext/NSDQ: ARGX)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital